SEARCH

SEARCH BY CITATION

References

  • 1
    Raraty MG, Magee CJ, Ghaneh P, Neoptolemos JP. New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol 2002; 41:58295.
  • 2
    Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185:47680.
  • 3
    Jaffee EM, Hruban RH, Biedrzycki B et al. Novel allogeneic granulocyte–macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19:14556.
  • 4
    Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3:66675.
  • 5
    Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:234657.
  • 6
    Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86:115966.
  • 7
    Dudley ME, Wunderlich JR, Yang JC et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25:24351.
  • 8
    Dudley ME, Wunderlich J, Nishimura MI et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24:36373.
  • 9
    Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10:6739.
  • 10
    Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 2001; 7:33438.
  • 11
    Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 2001; 97:29037.
  • 12
    Frolkis M, Fischer MB, Wang Z, Lebkowski JS, Chiu CP, Majumdar AS. Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors. Cancer Gene Ther 2003; 10:23949.
  • 13
    Sievers E, Albers P, Schmidt-Wolf IG, Marten A. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J Urol 2004; 171:11419.
  • 14
    Mizumoto K, Tanaka M. Detection of telomerase activity in patients with pancreatic cancer. Methods Mol Med 2004; 103:199206.
  • 15
    Schmidt J, Ryschich E, Sievers E, Schmidt-Wolf IG, Büchler MW, Märten A. Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo. Cancer 2006; 106:75964.
  • 16
    Mühlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997; 185:19518.
  • 17
    Serba S, Schmidt J, Wentzensen N, Ryschich E, Märten A. Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma. Gut 2008; 57:34451.
  • 18
    Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999; 180:1018.
  • 19
    Keith WN, Jeffry Evans TR, Glasspool RM. Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol 2001; 195:40414.
  • 20
    White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 2001; 19:11420.
  • 21
    Ayyoub M, Migliaccio M, Guillaume P et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 2001; 31:264251.
  • 22
    Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001; 61:338893.
  • 23
    Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000; 97:4796801.
  • 24
    Minev BR, Chavez FL, Mitchell MS. Cancer vaccines: novel approaches and new promise. Pharmacol Ther 1999; 81:12139.
  • 25
    Nair SK, Heiser A, Boczkowski D et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:101117.
  • 26
    Ma A, Boone DL, Lodolce JP. The pleiotropic functions of interleukin 15: not so interleukin 2-like after all. J Exp Med 2000; 191:7536.
  • 27
    Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001; 14:10510.
  • 28
    Mehrle S, Frank S, Schmidt J, Schmidt-Wolf IG, Märten A. SAP and SLAM expression in anti-CD3 activated lymphocytes correlates with cytotoxic activity. Immunol Cell Biol 2005; 83:339.
  • 29
    Mehrle S, Schmidt J, Buchler MW, Watzl C, Märten A. Enhancement of anti-tumor activity in vitro and in vivo by CD150 and SAP. Mol Immunol 2008; 45:796804.
  • 30
    Anasetti C, Mule JJ. To ablate or not to ablate? HSCs in the T cell driver's seat. J Clin Invest 2007; 117:30610.
  • 31
    Gupta S, Bi R, Su K, Yel L, Chiplunkar S, Gollapudi S. Characterization of naive, memory and effector CD8+ T cells: effect of age. Exp Gerontol 2004; 39:54550.
  • 32
    Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:70812.
  • 33
    Klebanoff CA, Gattinoni L, Torabi-Parizi P et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005; 102:95716.